NCT00281541View on ClinicalTrials.gov

A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

PHASE2CompletedINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

June 30, 2007

Conditions

Melanoma

Interventions

DRUG

YM155

Trial Locations (9)

15213

Pittsburgh

20010

Washington D.C.

27157

Winston-Salem

30322

Atlanta

72205

Little Rock

80045

Aurora

84112

Salt Lake City

85724

Tuscon

07042

Montclair

Sponsors

Lead Sponsor

Astellas Pharma Inc

All Listed Sponsors

collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT00281541 - A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma | Biotech Hunter | Biotech Hunter